tbuckley/cabot-search huggingface dataset:
RTHP-03. PROGNOSTIC IMPACT OF TIMING BETWEEN SURGERY AND RADIOTHERAPY (RT) IN PATIENTS WITH GLIOBLASTOMA (GBM)
Authors: Neil Chevli, Hesham Elhalawani, Abdallah Mohamed, Anita Mahajan, Jeffrey S Weinberg, Clifton David Fuller, Caroline Chung
Journal: Neuro-Oncology (2017)

This retrospective study evaluates whether the time interval between surgical resection and start of radiotherapy impacts outcomes in patients with newly diagnosed GBM. Adult patients with GBM who were followed with serial imaging after concurrent RT and temozolomide between January 2007 and December 2013 at a single tertiary cancer center were included. Prognostic factors including age, Karnofsky performance status (KPS), extent of surgery, and interval between surgery and start of RT were collected. Extent of surgery was categorized as either gross total resection (GTR) or other. Outcomes included overall survival (OS) and progression free survival (PFS). Univariate (UVA) and multivariable (MVA) analyses were conducted using cox proportional hazard models. A total of 150 patients with median age of 55 (range 21-73) were analyzed. Median time interval was 26 days [interquartile range (IQR) 21-33, range 8-62] and median survival was 26 months [IQR 12-49, range 0-98]. On UVA, age (HR 1.03, p< 0.0001; CI 1.02-1.05), KPS (HR 0.97, p= 0.001; CI 0.95-0.99), and GTR (HR 0.65, p= 0.03; CI 0.44-0.95) were prognostic for OS, whereas shorter time interval (HR 1.3, p= 0.17; CI 0.89-1.90) was not prognostic for OS. Shorter time interval (HR 1.39, p= 0.06; CI 0.99-1.96) was also not prognostic for PFS. On MVA, age (HR 1.03, p= 0.0002; CI 1.02-1.05), KPS (HR 0.98, p= 0.02; CI 0.96-0.99), and GTR (HR= 0.65, p= 0.03; CI 0.44-0.96) were independent predictors for OS. Within this cohort of patients who largely started RT between 3 to 5 weeks of surgery, the particular time interval between surgery and RT was not prognostic for OS or PFS. Studies that include patients with longer time intervals between surgery and RT may identify a threshold time interval beyond which time interval becomes negatively prognostic for OS.
Abstract 19191: A Mouse Model for Coronary Collateral Growth Validated Via Micro-CT and Echo-Contrast
Authors: Weiguo Wan, Sofia Chinchilla, Cui Zhang, Anurag Jamaiyar, Molly Enrick, Zhorro Nikolov, Christopher Kolz, Vahagn Ohanyan, William Chilian, Liya Yin
Journal: Circulation (2017)

Patients with an undeveloped collateral circulation have a poorer prognosis than those with well-developed collaterals when they have ischemic heart disease. Despite this great importance of the co...
Partial splenic embolization in chemotherapy-induced thrombocytopenia: a retrospective analysis with long term follow up
Authors: L. Procaccio, M. Schirripa, C. Aliberti, F. Bergamo, V. Dadduzio, S. Finotto, F. Loupakis, A. Menichetti, V. Zagonel
Journal: Annals of Oncology (2017)
NCOG-14. NEUROCOGNITIVE FUNCTION AND QUALITY OF LIFE IN STABLE GRADE II AND III GLIOMA PATIENTS
Authors: Tracy Luks, Angela Jakary, Susan Chang, Jennifer Clarke, Nicholas Butowski, Nancy Ann Oberheim-Bush, Sarah Nelson, Jennie Taylor
Journal: Neuro-Oncology (2017)

Neurocognitive function and quality of life are important clinical outcome measures for patients with lower grade glioma. Here, we performed neurocognitive testing and quality of life assessments in radiologically and clinically stable grade 2 and 3 glioma patients who are not receiving active treatment. Patients completed a computerized battery of standardized neurocognitive tests in the NIH Toolbox and quality of life assessments with the FACT-BR. We acquired patient demographic information, current performance status, current anti-epileptic therapy, treatment history, extent of resection at diagnosis and recurrence, tumor location, and histologic and molecular tumor characteristics. Tumor volumes were measured on T2 FLAIR MRIs. We have enrolled 15 patients. All patients had previous resection (10 partial, 5 gross total), 11 received chemotherapy, and 6 prior radiation. Median age at testing was 41 years old (range 26 – 65). As a group, patients were impaired on processing speed and fluid cognition. Two patients were impaired on picture vocabulary, 6 on list sorting, 11 on processing speed, 6 on sequence memory, 4 on inhibitory control, 2 on dimensional change, 7 on fluid cognition, and 0 on crystallized cognition. Higher age was significantly associated with poorer age-corrected oral-reading, and sequence memory. Insula and parietal lesions were associated with slower processing speed. Previous chemotherapy treatment was associated with poorer dimensional change. On imaging, larger tumor volumes were associated with poorer list sorting, processing speed, and sequence memory. On the FACT-BR, older patients, patients with prior radiation or those with higher grade were associated with poorer social/family well-being. The NIH Toolbox and FACT-BR are effective, accessible tools to assess neurocognitive function and quality of life in glioma patients. By correlating these assessments with patient and tumor characteristics, it may be possible to identify patients at risk for specific deficits and provide opportunity for intervention.
Intensive Blood Pressure Control in Autosomal Dominant Polycystic Kidney Disease—How Safe Is It?—Reply
Authors: Wan-Chuan Tsai, Kuo-Liong Chien, Hon-Yen Wu
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
GENE-05. IMPLICATIONS OF SPATIAL INTRATUMORAL MUTATIONAL HETEROGENEITY FOR PRECISION MEDICINE-GUIDED TREATMENT IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Authors: Tatenda Mahlokozera, Ananth Vellimana, Tiandao Li, Diane Mao, Zohny Zohny, David Kim, David Tran, Daniel Marcus, Sarah Fouke, Jian Campian, Gavin Dunn, Christopher Miller, Albert Kim
Journal: Neuro-Oncology (2017)

Diagnostic workflows for GBM patients increasingly include DNA sequencing-based analysis of a single tumor site following tumor biopsy or resection. Recent studies have highlighted the significant intratumoral heterogeneity of both treatment naïve and recurrent tumors in glioblastoma. We hypothesized that sequencing of multiple sectors within a given tumor would provide a more comprehensive representation of the molecular landscape than data from a single site and inform therapeutic strategies. We show that across 10 tumors subjected to whole-exome sequencing of multiple tumor sectors, 54% of mutations were shared between sectors (51% clonal and 3% subclonal), while 46% were subclonal and private. Among the canonical GBM-associated genes, only TERT promoter mutations were observed in the founding clone in all tumor sectors across all cases. Despite being treatment naïve, two of the 10 tumors exhibited a hypermutator state, which has been shown to predict response to immune checkpoint inhibitor therapy. Critically, the high mutational load was predominantly limited to one sector in both cases. Analysis of clonal architecture, inferred from variant allele frequencies of single nucleotide variants in copy-number neutral regions, demonstrated significant differences between sectors in 8 of 10 cases, suggesting regionally divergent evolution. Predicted therapeutically relevant mutations, based on exploratory analysis of the Drug Gene Interaction database (DGIdb), differed in presence and frequency between tumor sectors, with 74% of mutations across all tumors being private to one region. 80% of tumors had at least one private therapeutically relevant mutation. Similarly, different sectors exhibited significant divergence in the predicted neoantigen landscape, based on the pVAC-seq pipeline, with all 10 tumors harboring private neoantigens. Overall, 55% of predicted neoantigens were subclonal and private. These results suggest that multi-site analyses may be necessary to thoroughly characterize individual GBM tumors and precisely guide personalization of molecular and immune-based therapies.
ANGI-07. OXIDIZED MIF DRIVES GLIOBLASTOMA CELL INVASION DURING BEVACIZUMAB RESISTANCE THROUGH UNIQUE SIGNALING MECHANISMS
Authors: Daniel Hoffman, Alan Nguyen, Arman Jahangiri, Patrick M Flanigan, Jung Ming George Lin, Sanjay Kumar, Manish Aghi
Journal: Neuro-Oncology (2017)

Bevacizumab, an anti-VEGF monoclonal antibody, initially showed promising results as an anti-angiogenic therapy in treatment of glioblastoma. However, further trials demonstrated lack of durable efficacy and no improved overall survival, with resistant tumors displaying increased invasion. We recently identified reduced Macrophage Migratory Inhibitory Factor (MIF), a pleiotropic cytokine with known immunomodulatory and inflammatory properties, as a driver of bevacizumab resistance (Oncogene 2017). Oxidized MIF (oxMIF) is a recently discovered immunologically distinct, redox-dependent isoform expressed only in inflammatory settings such as autoimmune disease or cancer and is targeted by imalumab (BAX69; Baxalta), an anti-oxMIF antibody under phase I trials in solid cancers. We investigated the role of oxMIF in bevacizumab-resistant glioblastoma. We used imalumab to isolate the effects of non-oxMIF versus oxMIF signaling in glioblastoma. While bevacizumab-resistant xenografts expressed far less total MIF than bevacizumab-responsive xengorafts (P=0.003), resistant xengografts expressed more oxMIF (6745.79 vs. 3662 pg/mL, P=0.001). Hypoxia and reactive oxygen species, characteristics of the microenvironment in bevacizumab-treated glioblastoma, drove MIF oxidation (P=0.002). Neither oxMIF nor non-oxMIF drove proliferation in cultured glioblastoma cells (P≥.06). OxMIF inhibition reduced invasion of bevacizumab-naïve and bevacizumab-resistant GBM in matrigel (P=0.002) and bioengineered 3D hyaluronic acid-based (P<0.0001) assays but inhibition of all MIF did not (P=0.2). These discordant effects of oxMIF vs. non-oxMIF on invasion were mediated through reduced Src signaling rather than the CD74-CD44 signaling cascade utilized by non-ox MIF. Both oxMIF and non-ox MIF drove M1 macrophage polarization in culture and in vivo. In follow up to our finding that bevacizumab-resistant GBMs express reduced MIF, which shuts down MIF-driven M1 macrophage polarization and enriches for pro-tumoral M2 macrophages, we showed that the microenvironment of bevacizumab-resistant GBMs increases MIF oxidation in these tumors, driving invasion in a manner specifically targetable by imalumab. Further studies of imalumab for bevacizumab-resistant GBMs are warranted.
P1.05-010 Curative Treatment Rates for Patients Diagnosed with Early Stage Non-Small Cell Lung Cancer (NSCLC) in England
Authors: A. Khakwani, S. Harden, D. Baldwin, K. Foweraker, N. Navani, R. Dickinson, D. West, P. Beckett, R. Hubbard
Journal: Journal of Thoracic Oncology (2017)
RTHP-23. ADJUVANT THERAPY FOR HIGH-RISK WHO GRADE II OLIGODENDROGLIOMA AFTER RTOG 9802: A SURVEY OF CURRENT PRACTICE
Authors: Mohamad Fakhreddine, Anand Parameswaran, John Floyd, Andrew Brenner, Richard Crownover
Journal: Neuro-Oncology (2017)

RTOG 9802 long-term results (NEJM, April 2016) demonstrated significant improvements in overall survival with chemoradiotherapy (CRT) compared to radiotherapy alone, for patients with low-grade, high-risk supratentorial oligodendroglioma. Before publication of RTOG 9802, many such patients were not managed with CRT. This survey study probed treatment practices and whether additional therapy is being offered to patients who did not receive CRT prior to RTOG 9802. An anonymous internet-based survey containing 15 questions was sent to SNO membership. Questions queried treatment practices before and after RTOG 9802. A total of 128 responses were collected. Before RTOG 9802 publication, 82% (p=0.0001) of surveyed oncologists agreed that patients with sub-total resection should receive treatment, while there was not a statistical majority for patients with gross total resection (44%, p=0.18). Among oncologists favoring treatment for any high-risk patient, most (67%, p<0.0001) would include radiation. Only a minority favored CRT as the modality of choice. After publication of RTOG 9802, most oncologists favored treating high-risk patients (>70%, p<0.05). A majority (59%, p=0.002) would treat with sequential CRT compared to only 28% (p<0.0001) prior to RTOG 9802. Only 23.1% (p<0.0001) of oncologists favored bringing back patients who had not received CRT for further therapy. Among oncologists favoring additional therapy, most would treat patients who had not received any adjuvant therapy (85%, p=0.0004) and would treat with CRT (80%, p=0.007). There was no majority opinion regarding patients who had received single modality treatment. While most respondents favor treatment with CRT for high-risk patients, most would not offer additional therapy to patients who did not receive CRT prior to RTOG 9802 publication. Further investigation is warranted, given the potential for high impact on outcomes and lack of robust consensus.
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma
Authors: Mauro P. Avanzi, Renier J. Brentjens
Journal: Journal of the National Comprehensive Cancer Network (2017)

Adoptive T-cell therapy with chimeric antigen receptor T cells (CAR-Ts) has produced impressive clinical responses among patients with B-cell malignancies, and several groups have published positive results using anti-CD19 CAR-Ts for the treatment of B-cell acute lymphoblastic leukemia. Recently, new data from clinical trials have demonstrated the benefits of CAR-T therapy in the non-Hodgkin's lymphoma (NHL) setting. This review describes some of the most recent and promising advances in engineered T-cell therapy, with particular emphasis on the clinical benefits of NHL treatment.
Deux épidémies de rougeole en Allemagne, 2005
Authors: A Siedler, A Tischer, A Mankertz, S Santibanez
Journal: Eurosurveillance (2006)

En Allemagne, certains districts ont connu une re-emergence de la rougeole en 2005, malgre un taux de couverture vaccinale en hausse chez les enfants a l’entree de l’ecole ces dernieres annees, qui avait conduit a une baisse de l’incidence (avec, en 2004, 0,2 cas pou 100 000 habitants, soit l’incidence la faible jamais rapportee). 
Des epidemies regionales ont ete detectees par le systeme de declaration obligatoire dans les etats de Hesse et de Baviere. Les incidences dans les deux epidemies etaient similaires dans les regions touchees (respectivement 14 et 12 cas pour 100 000 habitants), mais la distribution selon l’âge, le mode de transmission et le genotype viral etaient differents. 
Dans l’etat de Hesse, 223 cas ont ete analyses, dont 160 appartenant a 41 clusters essentiellement familiaux ou definis par contacts au sein d’un meme foyer. Le taux d’attaque le plus important concernait les enfants entre 1 et 4 ans (102 cas pour 100 000). Les resultats du diagnostic viral montrent que tous les cas de Hesse analyses partage le meme genotype D4 et des sequences nucleotidiques identiques.
En Baviere, 279 cas ont ete rapportes, la plupart etaient survenus dans un environnement scolaire ou pre-scolaire. Le taux d’attaque le plus eleve concernait les enfants entre 5 et 9 ans (129 pour 100 000). Le diagnostic microbiologique a permis d’identifier le genotype viral D6. Les souches avaient des sequences nucleotiques identiques.
Dans ces deux epidemies, une forte majorite de cas (95% dans l’etat de Hesse et 98% en Baviere) etaient des enfants non vaccines, mais la couverture vaccinale etait differente selon la region concernee, et etait legerement plus faible en Baviere. Avant cette epidemie, la Baviere avait connu, une augmentation locale du nombre d’enfants non vaccines, et une concentration de ces enfants dans les ecoles et jardins d’enfants. 
Malgre un niveau moyen eleve de couverture vaccinale, des variations locales peuvent conduire a des epidemies limitees regionalement.
Toxi-infecciones alimentarias por Norovirus, ligadas al consumo de ostras del estanque de Thau, Francia, Diciembre 2002
Authors: A Doyle, D Barataud, A Gallay, J M Thiolet, S Le Guyaguer, E Kohli, V Vaillant
Journal: Eurosurveillance (2004)

En enero del 2003, el Institut de veille sanitaire fue alertado de la existencia de brotes de gastroenteritis probablemente asociados al consumo de ostras cultivadas en el estanque de Thau en el sur de Francia. Durante este mismo periodo, en Italia se declaro un brote con mas de 200 casos, asociado al consumo de ostras procedentes de este estanque.
Se llevo a cabo una encuesta para determinar la fuente y el vehiculo de estas epidemias.
Se realizaron los siguientes estudios: Analisis descriptivo de los brotes declarados en Francia, analisis microbiologico de las muestras de heces y de ostras, un genotipado de los norovirus, asi como una investigacion medioambiental del estanque de Thau. Tambien se realizo un estudio de cohorte retrospectivo entre las personas que habian participado en comidas familiares en Paris. Segun los resultados del analisis descriptivo, 13 brotes familiares en cuatro departamentos (69 casos) han podido ser atribuidos al consumo de las ostras de Thau. Ostras distribuidas en un establecimiento en Paris y luego consumidas en 14 comidas familiares entre el 19 y el 24 de diciembre causaron otra epidemia. La tasa de ataque fue de 21/36 (58%) en aquellos que habian consumido ostras y de 0/22 en aquellos que no habian consumido (p=0.00002). 
Los norovirus (genogrupos I y II) fueron identificados en muestras de heces de cuatro hogares infectados, y en las ostras en tres hogares (incluido Paris). Las investigaciones ambientales han revelado que hubo fuertes precipitaciones, desbordamiento de las estaciones de depuracion y contaminacion fecal del estanque de Thau en el mes de diciembre.
Las ostras del estanque de Thau fueron responsables en varios hogares de gastroenteritis por norovirus en el invierno de 2002 en Francia y en Italia.
Debido a los altos niveles de E.Coli encontrados en el agua del estanque y dentro de las conchas, se realizo una peticion oficial de depuracion de las ostras antes de la distribucion. Esta medida no pudo ser llevada a cabo por falta de un equipamiento suficiente.
Esta investigacion ha permitido cambiar la manera de clasificar las zonas de cultivo de moluscos en Francia.
P1.01-058 Real World Data with Nivolumab: Experience in Argentina
Authors: C. Martin, L. Lupinacci, F. Perazzo, C. Bas, O. Carranza, C. Puparelli, R. Kowalyzyn, I. Magri, M. Varela, E. Richardet, K. Vera, S. Foglia, I. Jerez, E. Aman, G. Martinengo, E. Batagel, A. Dri, N. Pilnik, M. Roa, P. Mando, F. Tsou, G. Recondo, F. Cayol, F. Marcos, S. Sena, C. Bagnes, J. Minatta, M. Rizzo
Journal: Journal of Thoracic Oncology (2017)
PATH-14. SIZE OF INCIDENTALLY DISCOVERED DIFFUSELY INFILTRATING GLIOMAS PREDICTS FUTURE GROWTH RATE
Authors: Magalie Cadieux, Michael Opoku-Darko, John Kelly
Journal: Neuro-Oncology (2017)

Incidentally discovered diffusely infiltrating gliomas (iDIGs) are lesions found on brain imaging for a reason not attributable to the lesion. Patients are usually asymptomatic at time of discovery. Incidentally DIGs can harbor different genetic abnormalities and vary widely in size at diagnosis. We hypothesized that tumor size at the time of diagnosis and histologic subtypes predict growth rate for these tumors. We reviewed all low-grade glioma cases at our institution. We identified 455 gliomas treated surgically from 2003 to 2016. Of these, 24(0.05%) cases were found to be iDIGs and to have serial imaging. Serial tumor volumes at minimum 3 month intervals were measured using OsiriX® software. Regions of interest were demarcated on axial FLAIR/T2 MRI sequences. The characteristics of the tumor (molecular genetics, extent of resection) were compiled. We compared tumor size at the time of initial diagnosis of these 24 iDIGs within pathologic subgroups and computed their respective growth rate using serial tumor volume measurement. The median growth rate of our series of iDIGs is 2.41mm/year. The median tumor size at initial diagnosis was 36.8 cm3. We separated iDIGS into small (<36.8 cm3) and large (>36.8 cm3) tumors. There were 5 large astrocytomas and 7 small astrocytomas. The mean growth rate at initial diagnosis for large astrocytomas (n=7) was 3.70 mm/year compared to 2.93 mm/year for small astrocytomas (n=5). By comparing the large and small oligodendrogliomas (n=2; n=9), larger oligodendroglioma grew at a faster rate (2.88 mm/yr vs 2.75 mm/yr). Also, when small astrocytomas were compared to small oligodendrogliomas, growth velocity was faster for the astrocytomas (2.93 mm/yr vs 2.75 mm/yr). Both size at identification and histologic subtype of iDIGS indicates future growth rate. Since growth rate velocity is a predictor for malignant transformation early treatment may impact overall survival.
SURG-36. REAL-WORLD TREATMENT FOR GLIOMA PATIENT: PRELIMINARY RESULTS OF A SERIES OF 525 CASES AT SUN YAT-SEN UNIVERSITY CANCER CENTER
Authors: Yinsheng Chen, Yonggao Mou, Xianghen Zhang, Ke Sai, Qunying Yang, Zhongping Chen
Journal: Neuro-Oncology (2017)

Treatments for gliomas are complex even though there are guidelines could be followed since variety of patient selection and doctor’s decision. Between January 2000 and December 2014, all glioma patients firstly surgically treated at the Sun Yat-sen University Cancer Center were retrospectively reviewed (All the patients were pathologically confirmed gliomas). The patients were then followed by real-world treatment. With follow-up to end of 2015，Survival was estimated by Kaplan-Meier analysis. Among 525 patients, 35 (6.7%) were diagnosed with WHO grade Ⅰ gliomas, 129 (24.6%) with grade Ⅱ gliomas, 162 (30.9%) with grade Ⅲ gliomas and 199 (37.9%) with glioblastomas, respectively. All the patients were treated with surgery, of 186 patients who received postoperative radiotherapy, 125 were high-grade gliomas (WHO grades Ⅲ and Ⅳ) and 61 were low-grade gliomas (WHO grades Ⅰ and Ⅱ). Among 138 who received adjuvant chemotherapy, 113 were high-grade gliomas and 25 were low-grade gliomas. The 1-, 3- and 5-year overall survival of 525 patients was 79.3%, 53.9% and 45.5%, respectively. The 5-year overall survival of the patients with gliomas of WHO grade Ⅰ, Ⅱ, Ⅲ and Ⅳ was 90.2%, 61.1%, 43.6% and 26.4%. In comparison with the literature reports, the prognosis of glioma patients treated at our cancer center, are much better especially the 5-year survival rate of the high-grade gliomas. Key words: Glioma; Overall survival; Real-world treatment.
P2.05-051 Safety of Lung Stereotactic Body Radiotherapy (SBRT): A Single Institution Prospective Study Based on RTOG 0915 Protocol Constraints
Authors: Valentina Vanoni, Anna Delana, Andrea Martignano, Salvatore Mussari, Christine Seebacher, Emanuela Vattemi, Antonello Veccia, Luigi Tomio
Journal: Journal of Thoracic Oncology (2017)